New drug combo shows early promise for tough lymphoma

NCT ID NCT05083208

Terminated Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a combination of two drugs, parsaclisib and chidamide, in 12 people with relapsed or refractory peripheral T-cell lymphoma. The goal was to find a safe dose and see if the combination could shrink tumors. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: parsaclisib and chidamide
What this could lead to: If it works, this combination could offer a new treatment option for people with hard-to-treat peripheral T-cell lymphoma.
What could go wrong: This is a very early (Phase 1) trial that was terminated early with only 12 participants. The results may not be reliable, and the combination may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL T-CELL LYMPHOMA

Contacts and locations

Locations

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university

Zhengzhou, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.